Oklahoma Medicaid spending on GLP-1 drugs

How much did Oklahoma Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $83.6 million for GLP-1 drugs paid through Oklahoma Medicaid in 2025, across at least 82,365 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 66 rows of 264, so these figures are floors.

Pharmacies were reimbursed at least $19.7 million for GLP-1 drugs paid through Oklahoma Medicaid in 2026 (quarter 1 only, as posted so far), across at least 19,435 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 25 rows of 75, so these figures are floors.

By year and ingredient

2020at least $421,876No data$4,027,760at least $1,750,986at least $607,985$40,557$71,648at least $6,920,813
2021at least $1,289,264No data$4,517,484$7,008,237at least $195,712$67,679at least $41,317at least $13,119,693
2022at least $3,994,025at least $572,495$5,103,306$23,514,151at least $41,042$128,156$50,339at least $33,403,514
2023at least $7,393,687$5,005,450$5,287,391$45,459,844at least $42,014$134,273Suppressedat least $63,322,659
2024at least $19,440,294$10,327,217at least $3,242,406$46,096,525at least $112,755at least $42,612at least $45,705at least $79,307,513
2025at least $23,016,465at least $15,277,591at least $1,398,516$43,861,541at least $9,111at least $10,233Suppressedat least $83,573,455
2026 (Q1)at least $5,684,067at least $3,876,292at least $222,343$9,889,332SuppressedSuppressedSuppressedat least $19,672,034

By product, 2025

Ozempic$21,325,08921,5390 of 24
Rybelsus$818,8078190 of 24
Wegovyat least $872,568at least 62218 of 40
Mounjaro$15,277,59113,9230 of 48
ZepboundSuppressedSuppressed1 of 1
Liraglutide (generic name listing)at least $807,812at least 1,52017 of 47
Victoza$590,7048680 of 16
Trulicity$43,861,54143,0510 of 32
BydureonSuppressedSuppressed4 of 4
Byettaat least $9,111at least 117 of 8
Exenatide (generic name listing)SuppressedSuppressed4 of 4
Soliquaat least $10,233at least 127 of 8
XultophySuppressedSuppressed8 of 8

By quarter, 2025

Q1 2025at least $20,052,744at least 18,67815 of 64
Q2 2025at least $20,820,362at least 20,54219 of 69
Q3 2025at least $21,101,268at least 21,29013 of 63
Q4 2025at least $21,599,081at least 21,85519 of 68

By quarter, 2026 (posted so far)

Q1 2026at least $19,672,034at least 19,43525 of 75

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.